Aduhelm Label Update Includes Seizure Risk And Recommends More MRIs
Executive Summary
New safety information may help defense of CMS's coverage restrictions. FDA updated the prescribing information for Biogen’s Alzheimer's therapy after four cases of seizures were reported in a trial.
You may also be interested in...
Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
CMS Strayed From Its Lane With Alzheimer’s Drugs Decision, US Congressional Republicans Say
Recent congressional reactions to the Medicare national coverage determination offers insight into policies around CMS decision-making that could advance if Republicans gain more control in Congress in 2023.
Medicare Alzheimer’s Decision Varies Evidence Mandate For Accelerated vs. Traditional Approvals
Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.